JPM2018: Nevro Announces FDA Nod For Next-Gen Senza II Device

Redwood City, Calif.-based device-maker Nevro Corp. kicked off the annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 8 with the announcement it received US FDA approval for its next-generation Senza II spinal cord stimulation system and better-than-expected Q4 earnings results.

Nevro Corp.President and CEO Rami Elghandour started his company presentation at this year's J.P. Morgan Healthcare Conference on a high note by announcing that US FDA has given the nod of approval for the firm's next-generation Senza II spinal cord stimulation system, and noted that he expects more growth opportunities ahead for 2018.

"We see ample opportunity in 2018," Elghandour told the audience at the Jan

More from Regulation

More from Policy & Regulation